Skip to main content

Select Drug Profiles

Practice Management

Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil

Chamika Hawkins-Taylor, MHA, PhD, Angeline M. Carlson, PhD

Stakeholder Perspective

Much More than Biomarkers: Sociodemographic Variables in Personalized Medicine

by Michael F. Murphy, MD, PhD

Practice Management

Yet Another Blow to the Medicaid Expansion

Igor Gorlach, JD, MPH, Ross D. Margulies, JD, MPH

Original Research

New Drug Therapies for the Treatment of Overweight and Obese Patients

Babak Mahgerefteh, DO, Michael Vigue, DO, Zachary Freestone, DO, Scott Silver, DO, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

The Modern Epidemic of Obesity

by James V. Felicetta, MD

Cardiometabolic Risk Factors: Novel Approaches Can Improve Patient Outcomes

Dalia Buffery, MA, ABD

Practice Management

Assessing Medicare Beneficiary Eligibility for Medication Therapy Management Programs Using PINNACLE, a National Cardiovascular Data Registry

Sarah A. Spinler, PharmD, Mark J. Cziraky, PharmD, Fengming Tang, MS, Gladys G. Dueñas, PharmD, Tyan Thomas, PharmD, Jennifer A. Reinhold, PharmD, Vincent J. Willey, PharmD

Stakeholder Perspective

Hanging Together for Patient-Centered Medical Care

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Lisa A. Raedler, PhD, RPh

New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib Therapy from ASCO 2013 and EHA 2013

Lisa A. Raedler, PhD, RPh

Practice Management

FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials

Caroline Helwick

Lung Cancer, Oncology

Crizotinib Superior to Standard Chemotherapy in ALK-Positive Lung Cancer

Page 171 of 244
Results 1701 - 1710 of 2434